Health Exec: We Have No Choice But To Embrace AI
Providers who don't take advantage of AI will get "left behind," said Dr. Shantanu Gaur, founder and CEO of Allurion Technologies, during a panel discussion at INVEST Digital Health.
Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
presented by
What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
Allurion raises $27M to commercialize gastric balloon device in the U.S. and beyond
The swallowable balloon eliminates the need for endoscopy and anesthesia, reducing costs for patients – who are generally paying out of pocket.
Another startup hoping to tackle obesity using a device raises $19M
Allurion Technologies is seeking $27 million to bring its gastric balloon device, available in Europe, to the U.S. market to tackle the obesity epidemic.